{"id":556147,"date":"2021-08-04T19:18:01","date_gmt":"2021-08-04T19:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=556147"},"modified":"2021-08-04T19:18:01","modified_gmt":"2021-08-04T19:18:01","slug":"chemotherapyinduced-hearing-loss-market-insight-report-analysis-of-epidemiology-segmentation-treatment-landscape-market-size-emerging-drugs-and-key-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapyinduced-hearing-loss-market-insight-report-analysis-of-epidemiology-segmentation-treatment-landscape-market-size-emerging-drugs-and-key-companies-by-delveinsight_556147.html","title":{"rendered":"Chemotherapy-Induced Hearing Loss Market Insight Report: Analysis of Epidemiology Segmentation, Treatment Landscape, Market Size, Emerging Drugs and Key Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1628066459.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chemotherapy-Induced Hearing Loss Market Insight Report: Analysis of Epidemiology Segmentation, Treatment Landscape, Market Size, Emerging Drugs and Key Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1628066459.png\" alt=\"Chemotherapy-Induced Hearing Loss Market Insight Report: Analysis of Epidemiology Segmentation, Treatment Landscape, Market Size, Emerging Drugs and Key Companies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Chemotherapy-Induced Hearing Loss Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The dynamics of the Chemotherapy-Induced Hearing Loss market are likely to change due to an increase in the incidence of solid tumors treated with chemotherapy during the forecast period of 2021-2030. <\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/97375f652ad7a5621b00c33418794ca6.jpg\" alt=\"\" \/><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight&#8217;s <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-hearing-loss-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chemotherapy-Induced Hearing Loss market report<\/a><\/strong><span> examines historical and projected epidemiology, as well as Chemotherapy-Induced Hearing Loss market trends in the 7MM (the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan).<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Key Highlights from the Chemotherapy-Induced Hearing Loss Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>61%<\/strong><span> of patients globally had bilateral hearing loss. Hearing Loss was more common and severe in children treated for medulloblastoma, osteosarcoma, and neuroblastoma (Knight et al.).<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>As per DelveInsight analysis, Chemotherapy-Induced Hearing Loss affects <strong>young children more than adults.<\/strong><\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Some of the key players at the global level active in the Chemotherapy-Induced Hearing Loss market are <\/span><strong>Fennec Pharmaceuticals, Matrix Biomed, Sensorion, Sound Pharmaceuticals, <\/strong><span>and others.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Pedmark (sodium thiosulfate) (Fennec Pharmaceuticals)<\/strong><span> is a cisplatin neutralizing agent in development for the prevention of hearing loss in pediatric cisplatin chemotherapy patients. In March 2018, the FDA granted sodium thiosulfate breakthrough therapy and fast track designation.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>SENS-401 (Sensorion)<\/strong><span> is a novel drug candidate for the treatment of Sudden Sensorineural Hearing Loss (SSNHL). The FDA designated the drug as an orphan drug, and the European Medicines Agency approved a pediatric investigation plan (EMA).<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Find out which key player is expected to be at the forefront of the Chemotherapy-Induced Hearing Loss Market by requesting sample @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-hearing-loss-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chemotherapy and Ear Infection<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Chemotherapy-Induced Hearing Loss market report<\/strong><span> covers current treatment practices, emerging drugs, individual Chemotherapy-Induced Hearing Loss therapy market share, and current and forecasted Chemotherapy-Induced Hearing Loss market size from 2018 to 2030, segmented by seven major markets.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chemotherapy-Induced Hearing Loss: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>One of the most serious side effects of chemotherapy&nbsp; (platinum compounds) is hearing loss. It is caused by the degeneration of ear hair cells, which are unable to regenerate because they lack the ability to self-renew. Platinum-induced hearing loss is typically bilateral, sensorineural, and permanent. The higher frequencies (&gt;4000 Hz) are the first to be harmed, but even the lowest frequencies (500&ndash;4000 Hz), which are required to understand language, can be damaged over time.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chemotherapy-Induced Hearing Loss Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The Chemotherapy-Induced Hearing Loss report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing Loss Incident Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing Loss Age-Specific Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing Loss Severity-Specific Cases<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Chemotherapy-Induced Hearing Loss Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The current major Chemotherapy-Induced Hearing Loss treatment options include:<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Assistive devices<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Cochlear implant<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Otoprotective agents<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Hearing Aid<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Chemotherapy-Induced Hearing Loss Market<\/strong>&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The dynamics of the Chemotherapy-Induced Hearing Loss market are likely to change due to an increase in the incidence of solid tumors treated with chemotherapy during the forecast period of 2021-2030. The existing pipeline for Chemotherapy-Induced Hearing Loss is limited, but the launch of <\/span><span>Pedmark<\/span><span>, a late-stage product, has the potential to drive the Chemotherapy-Induced Hearing Loss market in the upcoming years.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get a detailed analysis of chemotherapy-induced hearing loss market @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-hearing-loss-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chemotherapy-Induced Hearing Loss Market Research<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Chemotherapy-Induced Hearing Loss Pipeline Therapies and Key Companies<\/strong>&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pedmark: Fennec Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Tempol: Matrix Biomed<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>SENS-401: Sensorion<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>SPI-1005: Sound Pharmaceuticals<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><span>&nbsp;<\/span><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"62\" \/>\n<col width=\"562\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing Loss: Market Overview at a Glance<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Executive Summary<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disease Background and Overview: Chemotherapy-Induced Hearing Loss<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Organization<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Patient Journey<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>KOL<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Case Study<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing Loss Epidemiology and Patient Population&nbsp;&nbsp;<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing Loss: Country-wise Epidemiology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing Loss Treatment &amp; Medical Practices<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing Loss Emerging Therapies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Pedmark: Fennec Pharmaceuticals<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing loss: Market Size<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing Loss Country-wise Market Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>16.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing Loss Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>17.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing Loss Market Drivers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>18.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing Loss Market Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>19.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Chemotherapy-Induced Hearing Loss Market Access<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>20.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Report Methodology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>21.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DelveInsight Capabilities<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>22.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disclaimer<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>23.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For rich insights into Healthcare and Pharmaceutical News, visit <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-nausea-and-vomiting-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chemotherapy-Induced Nausea and Vomiting Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get comprehensive historical and forecast analysis of <\/span><span>Chemotherapy-Induced Nausea and Vomiting<\/span><span> Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as <\/span><span>Camurus, LP Pharmaceuticals, Skye Bioscience, TALLC Corporation<\/span><span>, <\/span><span>Starton Therapeutics<\/span><span>, among others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chemotherapyinduced-hearing-loss-market-insight-report-analysis-of-epidemiology-segmentation-treatment-landscape-market-size-emerging-drugs-and-key-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chemotherapyinduced-hearing-loss-market-insight-report-analysis-of-epidemiology-segmentation-treatment-landscape-market-size-emerging-drugs-and-key-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chemotherapy-Induced Hearing Loss Market The dynamics of the Chemotherapy-Induced Hearing Loss market are likely to change due to an increase in the incidence of solid tumors treated with chemotherapy during the forecast period of 2021-2030. DelveInsight&#8217;s Chemotherapy-Induced Hearing Loss market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapyinduced-hearing-loss-market-insight-report-analysis-of-epidemiology-segmentation-treatment-landscape-market-size-emerging-drugs-and-key-companies-by-delveinsight_556147.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-556147","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=556147"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556147\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=556147"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=556147"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=556147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}